Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
Yasuhiro Tsutani, Jonathan W. Goldman, Sanja Đačić, et al.
Clinical Lung Cancer (2023) Vol. 24, Iss. 4, pp. 376-380
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 2, pp. 137-147
Closed Access | Times Cited: 332
Top advances of the year: Targeted therapy for lung cancer
Maisam Makarem, Pasi A. Jänne
Cancer (2024) Vol. 130, Iss. 19, pp. 3239-3250
Closed Access | Times Cited: 6
Updates on lung adenocarcinoma: invasive size, grading and STAS
Jonathan Willner, Navneet Narula, André L. Moreira
Histopathology (2023) Vol. 84, Iss. 1, pp. 6-17
Open Access | Times Cited: 13
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
Oncologic Outcomes of Thoracoscopic Segmentectomy in Patients with High-Grade Adenocarcinoma Pattern
Stefano Bongiolatti, Alberto Salvicchi, Lavinia Gatteschi, et al.
Life (2025) Vol. 15, Iss. 3, pp. 339-339
Open Access
Place des thérapies ciblées en situation adjuvante au cours des cancers bronchiques non à petites cellules localisés
Nicolas Girard
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S46-3S51
Closed Access
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Jinyong Kim, Sehhoon Park, Bo Mi Ku, et al.
Cancer (2025) Vol. 131, Iss. S1
Closed Access
Molecular characterization of early-stage lung adenocarcinoma presenting as subsolid nodules in a real-life European cohort
Riccardo Tajè, Filippo Tommaso Gallina, M Caterino, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
EGFR mutation testing across the osimertinib clinical program
Marie Laure Murat-Onana, Suresh S. Ramalingam, Pasi A. Jänne, et al.
Lung Cancer (2025), pp. 108549-108549
Closed Access
Real‐World Treatment Patterns and Associated Outcomes in Patients With Resectable Early‐Stage Non‐Small Cell Lung Cancer: The THASSOS International Study
Kumar Prabhash, R. Moor, Tuncay Göksel, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 8
Open Access
EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system
Kotaro Nomura, Keiju Aokage, Yasunori Kaminuma, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 3, pp. 248-257
Open Access | Times Cited: 3
High-Risk Features Associated with Recurrence in Stage I Lung Adenocarcinoma
Cameron N. Fick, Elizabeth G. Dunne, Stijn Vanstraelen, et al.
Journal of Thoracic and Cardiovascular Surgery (2024)
Closed Access | Times Cited: 3
The Grading System for Lung Adenocarcinoma: Brief Review of its Prognostic Performance and Future Directions
José G. Mantilla, André L. Moreira
Advances in Anatomic Pathology (2024) Vol. 31, Iss. 5, pp. 283-288
Closed Access | Times Cited: 2
Liquid biopsy for the management of NSCLC patients under osimertinib treatment
Aliki Ntzifa, Theodoros Marras, Vassilis Georgoulias, et al.
Critical Reviews in Clinical Laboratory Sciences (2024) Vol. 61, Iss. 5, pp. 347-369
Closed Access | Times Cited: 1
Sublobar Resection vs Lobectomy for High-Risk Stage I Non–Small Cell Lung Carcinoma
Jay M. Lee
JAMA Oncology (2024) Vol. 10, Iss. 9, pp. 1173-1173
Closed Access | Times Cited: 1
EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer
Samantha Goffinet, Christophe Bontoux, Simon Heeke, et al.
Virchows Archiv (2024)
Closed Access | Times Cited: 1
Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation
Atsushi Osoegawa, Takashi Karashima, Yohei Takumi, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 10, pp. 5566-5573
Open Access | Times Cited: 3
Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
Gavitt A. Woodard, Sanja Đačić
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 5, pp. 663-665
Open Access
Clinical Role of Adjuvant Chemotherapy after Sublobar Resection for Non-small Cell Lung Cancer ≤ 20 mm with Lymph Node Metastases: A Propensity-Matched Analysis of the National Cancer Database
Shinkichi Takamori, Junjia Zhu, Asato Hashinokuchi, et al.
(2024)
Open Access
The Clinical Role of Adjuvant Chemotherapy after Sublobar Resection for Non-Small-Cell Lung Cancer ≤ 20 mm with Lymph Node Metastases: A Propensity-Matched Analysis of the National Cancer Database
Shinkichi Takamori, Junjia Zhu, Asato Hashinokuchi, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2176-2176
Open Access
Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma
S. Kubota, Tetsuro Taki, Tomohiro Miyoshi, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114184-114184
Closed Access
Treatment of cavitated non-small cell lung cancer presenting as “Halloween pumpkin” following the consecutive NEOADAURA and ADAURA2 strategy: A case report
Lingyun Wei, Nan Yang, Chuan Gao, et al.
Respiratory Medicine Case Reports (2024) Vol. 51, pp. 102089-102089
Open Access
Advancements in non-small cell lung cancer treatment: from early to advanced stages
Adam Płużański, Aleksandra Piórek
Oncology in Clinical Practice (2024)
Open Access
Proceedings of the 1st biannual bridging the gaps in lung cancer conference
Narjust Florez, Sandip Pravin Patel, Heather A. Wakelee, et al.
The Oncologist (2024)
Open Access
2024: zece ani de progrese în NSCLC EGFRm
Alexandru Grigorescu
Oncolog-Hematolog ro (2024) Vol. 3, Iss. 68, pp. 14-14
Open Access
Page 1 - Next Page

Scroll to top